LEP and obesity disorder: Combination of the SGLT2i Dapagliflozin and carbohydrate restriction in patients with T2D and obesity resulted in a significant reduction of weight, fat mass and serum leptin, with no discernible change in energy expenditure or appetite at 12 months.